ERBB2 and neoplasm: They constructed a dual-targeting exosome platform for T-cell CD3 and BC-specific human epidermal growth factor receptor 2 (HER2) receptors, which was capable of targeted activation of CD8+ T cells and potent killing of HER2 tumor cells, demonstrating promising immunotherapeutic effects.